Autoimmune haemolytic anaemia - management
AIHA mgmt · Haematology / Oncology
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Antibody-mediated red cell destruction, warm (IgG) or cold (IgM) type, confirmed by a positive direct antiglobulin test. Management targets the immune process, supports oxygenation, and seeks underlying lymphoproliferative or autoimmune disease.
Red flags
- Haemoglobin falling rapidly with cardiac compromise
- Haemoglobinuria with renal impairment
- Signs of lymphoma (nodes, B symptoms)
- Concurrent thrombocytopenia (Evans syndrome)
- Cold AIHA with acrocyanosis and massive agglutination
Assessment
Differential diagnosis
- Hereditary haemolytic anaemia (spherocytosis, G6PD)
- Microangiopathic haemolysis (TTP/HUS)
- Drug-induced haemolysis
- PNH
- Cold agglutinin disease
- Lymphoproliferative disorder
Investigations
- FBC, film (spherocytes, agglutination), reticulocytes
- Direct antiglobulin test (IgG and C3d pattern)
- LDH, haptoglobin, unconjugated bilirubin
- Thermal amplitude / cold agglutinin titre if cold type suspected
- Blood group and antibody screen (transfusion planning)
- Screen for secondary cause: CT, serum electrophoresis, autoimmune serology, viral screen
Management
- Confirm haemolysis (high LDH, high reticulocytes, low haptoglobin, high bilirubin) and positive DAT
- Classify warm vs cold by DAT pattern and thermal characteristics
- Assess severity and haemodynamic/cardiac impact
- For warm AIHA, start corticosteroids first line
- Add folic acid and thromboprophylaxis (active haemolysis is prothrombotic)
- Transfuse if critically symptomatic despite cross-match difficulty - give least-incompatible units, never withhold in emergency
- For refractory/relapsing warm AIHA use rituximab; consider splenectomy or further immunosuppression
- For cold agglutinin disease, keep the patient warm, avoid steroids/splenectomy, use rituximab-based therapy and consider sutimlimab
- Investigate and treat any secondary cause (lymphoma, CLL, SLE, infection)
- Taper steroids slowly once haemoglobin stabilises and monitor for relapse
Drugs & doses
Prednisolone 1 mg/kg PO daily (warm AIHA, then taper)
Methylprednisolone 1 g IV daily for 1-3 days in severe cases
Rituximab 375 mg/m2 IV weekly for 4 weeks (second line / cold agglutinin)
Folic acid 5 mg PO daily
Sutimlimab per protocol for cold agglutinin disease
Disposition
Admit if severe or rapidly falling Hb; haematology-led management; outpatient follow-up for taper and relapse monitoring.
Complications & pitfalls
- Venous thromboembolism during active haemolysis
- Steroid toxicity
- Relapse on tapering
- Transfusion reaction from pan-reactive antibodies
- Progression of underlying lymphoproliferative disease
Exam pearls
- Never withhold life-saving transfusion because of cross-match incompatibility
- Steroids are ineffective in cold agglutinin disease - keep warm and use rituximab
- Active haemolysis warrants thromboprophylaxis
- Always hunt for an underlying lymphoproliferative or autoimmune disorder
- Evans syndrome = AIHA plus immune thrombocytopenia
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.